Beyond the Bolus - Diabetes Technology Education for Healthcare Providers

By Insulet, Maker of OmnipodScience Education

Beyond the Bolus - Diabetes Technology Education for Healthcare Providers episodes

September 09 Tubeless Trendsetters: The Freedom Factor of Omnipod® 5 with Dr. David Ahn and Justin Eastzer
This month’s episode brings together two voices from different sides of diabetes care: Dr. David Ahn, endocrinologist and Chief of
Diabetes Services at Hoag Hospital's Mary and Dick Allen Diabetes Centre in Newport Beach, California, and Justin Eastzer, diabetes advocate known as @diabetech. Together with host Nancy Hanna, they dig into what going tubeless means for the people wearing it and the clinicians prescribing it.

Dr. Ahn shares how the absence of tubing helps patients overcome hesitation around starting pump therapy, particularly those concerned about visibility and medical stigma. He discusses the clinical impact of not needing to disconnect for daily activities*, including his personal experience of seeing how this can help reduce rebound hyperglycemia, and he also highlights how the simplicity of Omnipod 5 has been transformative for his older patient population. Justin offers a firsthand patient perspective on how the tubeless form factor gives him freedom across every area of daily life, from workouts to travel, getting dressed, without ever needing to think about where his pump is.

The conversation also covers the expanded site rotation options that come with a tubeless system, the convenience of the automated cannula insertion for those with needle phobia, and the latest Omnipod 5 software update featuring the lower 100 mg/dL Target Glucose setting. Dr. Ahn closes with how the free 30-day sample kit†† and single-prescription simplicity help clinicians get hesitant patients started.

Whether you're a clinician, educator, or someone
living with diabetes, this episode offers a compelling look at how removing tubing removes barriers to better outcomes.
----------
·       00:00 - Why tubeless matters: reducing stigma and starting AID
·       05:06 - The patient perspective: freedom in daily life
·       08:57 - Site rotation, waterproof form-factor†, and not needing to disconnect for daily activities*
·       11:41 - Automated insertion and simplicity for all ages
·       16:50 - Getting patients started with a single prescription for Omnipod 5
----------
* The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.
† Daily normal activities are related to recreational, educational, and occupational activities. The Pod must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment, and the Controller or smartphone should be placed outside of the procedure room. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide.
†† Omnipod® 5 Intro Kit 30-Day Trial
Terms and Conditions
1. Program Eligibility
Eligibility criteria: Subject to program limitations and terms and conditions, the Omnipod 5
Intro Kit 30-day trial program (the “Program”) is open to patients who have a valid Omnipod 5 prescription as well as a compatible CGM prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges. In order to be eligible, the patient’s eligible insurance plan must include coverage for Omnipod 5 Pods. The Program is open to new Pod Therapy patients coming from multiple daily injections or tubed pumps only who have not previously used Omnipod 5, Omnipod DASH® or Omnipod Insulin Management System.
This offer is not valid for participants whose Omnipod 5 or compatible CGM prescription is paid for in whole or in part by Medicare,
Medicaid, or any other federal or state programs. It is not valid for cash-paying participants or where prohibited by law. A participant is considered cash-paying where the participant has no insurance coverage for Omnipod 5 or where the participant has commercial or private insurance but Insulet determines in its sole discretion the participant is effectively uninsured because such coverage does not provide a material level of financial assistance for the cost of an Omnipod 5 prescription. Participants on certain commercial insurance plans may not be eligible. This offer is only valid in the United States, Puerto Rico, and the U.S. territories. Participants receiving their products through the Durable Medical Equipment or Pharmacy Durable Medical Equipment channel are not eligible to participate in the copay card program.
Please contact Insulet Customer Support at 1-800-591-3455 for details.
2. Program Details
With this program, Participants may be eligible to
receive a limited supply of Omnipod 5 products at no cost for them. Eligible participants have two (2) options, based on the following:
• A participant shall sign the Omnipod® 5 Intro Kit 30-Day Trial Acknowledgement through the appropriate platform provided by Insulet.
• Once Insulet has received the request, the request shall be escalated to Insulet’s pharmacy partner, where a request for a prescription shall be sent to the participant’s healthcare professional. If a valid prescription is received, both for the Omnipod 5 Intro Kit and the Omnipod 5 Pods, the participant’s benefits will be checked by Insulet or its partners.
   • IF the benefits check results in a monthly copay equal to or below two hundred dollars ($200), then Insulet shall issue a one-time only copay card to the participant, for a value equal to the out-of-pocket expenses the participant would have to pay for an Omnipod 5 Intro Kit, in accordance with Section 3, below.
   • IF the benefits check result in a copay greater than two hundred dollars ($200), Insulet, or its authorized partners, shall arrange for the shipment of one (1) Omnipod 5 Intro Kit, in accordance with Section 4, below.
   • For the purpose of clarity, the term “copay” shall encompass any out-of-pocket expense for one (1) month’s supply of Pods, including any deductible, copays and other out-of-pocket expenses that the participant would have to disburse to procure said supply of Pods.
   • Any copay assistance may not apply to a participant’s health plan’s deductible if prohibited by state law or by a health plan.
   • In order to use the Omnipod 5 System in Automated Mode, the User must also procure a compatible CGM. This program does not include supply of a compatible CGM.
Insulet reserves the right to change, amend or rescind this Program, in whole or in part, at any time.
3. Copay Card
Should participant be deemed eligible to receive an Omnipod 5 Copay Card, participant shall receive electronically one (1) Omnipod 5 Copay Card, valid for a single use, in the amount required for the participant to procure one (1) Omnipod 5 Intro Kit, which shall include:
• One (1) Omnipod 5 Controller
• Ten (10) Omnipod 5 Pods
• One (1) Omnipod 5 User Guide
• One (1) Controller charging cable
4. Product Dispense
Should participant be deemed eligible to receive a
one-time dispense of Omnipod 5 Pods at no cost to them, Insulet, or its
authorized partner, shall dispense one (1) Omnipod 5 Intro Kit, which shall
include:
• One (1) Omnipod 5 Controller
• Ten (10) Omnipod 5 Pods
• One (1) Omnipod 5 User Guide
• One (1) Controller charging cable
The Omnipod 5 Intro Kit shall be delivered to the shipping address indicated by participant in their Acknowledgment Form. Any estimate date of delivery is given solely for participant’s information and does not constitute a warranty that the Intro Kit will be delivered on said date. Participant is responsible to provide an accurate delivery address, to receive shipment of the Intro Kit and to verify the content of the Intro Kit.

How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?

Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D).

Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.

Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5.

If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you.

INS-OHS-07-2026-00089V1.0
20 min
August 11 Settings, Trust, and Time in Range: Optimizing Omnipod® 5 with Dr. Sufyan Hussain
Recorded live at the ADA Scientific Sessions New Orleans, Nancy Hanna sits down with Dr. Sufyan Hussain, Consultant Physician in Diabetes and Endocrinology at Guy's and St Thomas' NHS Foundation Trust and Honorary Academic at King's College London, to explore why real-world evidence matters as much as clinical trial data.
Dr. Hussain shares how real-world data helped secure widescale public funding for automated insulin delivery (AID) systems in the UK, and walks through practical, evidence-based recommendations for healthcare providers: using stronger Target Glucose, Insulin-to-Carb ratio (≤350/TDI) and Correction Factor (≤1500/TDI) settings1. He also discusses the importance of an independent, validated comparator like lab-based A1C when evaluating outcomes across systems.
The conversation also covers real patient stories, including individuals with
significant fear of hypoglycemia and lower health and tech literacy, who saw
meaningful improvements in time in range and A1C after starting on Omnipod 5. Dr. Hussain closes with a discussion on why simplicity and the tubeless form factor can be the deciding factor for patients who were previously hesitant to try pump therapy.
Whether you're a clinician, educator, or someone living with diabetes, this episode offers a compelling look at how real-world data is shaping the future of diabetes care.

00:00 - Why real-world evidence (RWE) matters
05:12 - Key real-world insights: Equity, simplicity, and outcomes
08:12 - Optimizing Omnipod 5 settings for improved clinical results
15:24 - Expanding access: Patient success stories and the power of simplicity

1. Sawyer A, et al. Diabetes Technol Ther. 2026 (T1D). Data on file. 2026.
RF-062026-00044 (T2D). Retrospective RWE of U.S. T1D and U.S. T2D users
utilizing optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day (T1D) or ≥3 bolus/day (T2D). Optimized settings: CF x TDI ≤1500, I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL.
How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?
Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (T1D) and type 2 diabetes (T2D).
Hosted by Insulet's Clinical Services Managers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)'s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.
Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5.
If you're looking to empower your patients to take back control of their diabetes, then this is the podcast for you.
24 min
July 08Enhanced Omnipod 5 Algorithm, Improved Outcomes, and What’s Next: Insulet’s ADA 2026 Highlights
What happens when cutting-edge innovation meets real-world results? At ADA 2026, the future of diabetes management came into sharper focus—and in this episode, we’re breaking it all down for you.
Join host Nancy Hanna alongside Medical Affairs experts Kellee Miller and Jennifer Boyd as they unpack the most exciting Insulet data emerging from this year’s Scientific Sessions in New Orleans. From the latest Omnipod® 5 enhancements—including a new lower glucose target and expanded sensor compatibilities —to early real-world insights showing meaningful gains in time in range1, the conversation is packed with breakthroughs that matter.
You’ll also get an inside look at the real-world glycemic outcomes using Omnipod Discover™, a powerful new data platform designed to enhance engagement with diabetes data2; the STRIVE trial exploring the next-generation Omnipod® 6 system*; and a vision for a fully closed-loop system for type 2 diabetes*, designed to reduce burden, simplify care, and expand access
Whether you’re a clinician, researcher, or passionate about advancing diabetes care, this is your front-row seat to the innovations shaping what’s next.
Time stamps:
1:10 Omnipod 5 is now even stronger, with a lower Target Glucose of 100 mg/dL & more time in Automated Mode
3:16 Discover™: Designed to streamline care and deliver meaningful insights
5:32 STRIVE*: Omnipod 6 pivotal trial shows strong glycemic outcomes with fewer boluses3
8:44 EVOLUTION 3*: Pre-pivotal study for Fully Closed Loop (FCL)* for type 2 diabetes4
Standard additional description for SEO purposes:
How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?
Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d).
Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.
Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer
insights into what the future of diabetes care could look like with devices like Omnipod 5.
If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you.
*CAUTION: Insulet’s Omnipod 6 and FCL System for type 2 diabetes are investigational devices. Limited by federal (or United States) law to investigational use. These products have not been reviewed by the FDA or any other regulatory agency.
Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-052026-00056
2. Insulet data on file. Pablo, M et al. Real-World Glycemic Outcomes Using the Omnipod Discover Data Management System. RF-062026-00008
3.Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-052026-00027
4. Insulet data on file. 2026. Presented at ADA 2026 June 5-8, New Orleans LA RF-062026-00015
 The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 Automated Insulin Delivery System is compatible with the following U-100 insulins: NovoLog®, Humalog®, Kirsty®, and Admelog®. Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT start to use the Omnipod® 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.
© 2026 Insulet Corporation. All rights reserved.
15 min
June 03 Omnipod® 5's 100 mg/dL Target Glucose setting and FreeStyle Libre 3 Plus sensor integration
Omnipod 5 is now even stronger with enhancements designed for more time in range1 and more time in Automated Mode. In this episode, we break down what they are and what they look like in practice.
Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE are joined by Dr. Nader Kasim, a pediatric endocrinologist at Corewell Health living with type 1 diabetes, to explore the latest updates coming to Omnipod 5.
Dr. Kasim shares his firsthand experience as a participant of the Limited Market Release of this product. He shares how the new 100 mg/dL Target Glucose setting increases the algorithm’s response to rising glucose levels to help him spend more time in range1 and how these enhancements can help keep users in Automated Mode longer.
The FreeStyle Libre 3 Plus sensor integration results in more personalized care and more real-time glucose monitoring data for caregivers with the LibreLinkUp app.
1. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting
demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057.
2:33 – More TIR with the 100mg/dL Target Glucose setting1
6:04 – How adjustable Target Glucose settings support confidence in day-to-day diabetes management
10:30 – Algorithm improvements designed for more time in Automated Mode
14:41 – Sensor choice and how some Libre 3 Plus sensor choice can help families simplify care

1. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting
demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Differences in mean TIR for 100mg/dL vs 110mg/dL, vs 120 mg/dL, vs 130 mg/dL, vs 140 mg/dL, vs 150 mg/dL, were 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. For each comparison, the lower bound of the one-sided 95% Confidence Interval (CI) was >0%, meeting the pre-specified superiority criterion. Analysis not controlled for ISF, ICR, % time in Automated Mode and number of bolus/day. Data on File. RF-012026-00057.
Standard additional description for SEO purposes: [MU2] How [MU3] do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?
Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d).
Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with
diabetes. Episodes cover a range of topics such as, how to get started with
Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.
Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5.
If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you.

The Omnipod 5 Automated Insulin Delivery System
is a single hormone insulin delivery system intended to deliver U-100 insulin
subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.
© 2026 Insulet Corporation. All rights reserved.

23 min
May 18 Mental Health, Automation, and Human-Centered Design: Rethinking Diabetes Care with AID Systems
Mental health, cognitive burden, and quality of life are becoming central to how we define success in diabetes care. In this episode, we explore what that shift looks like in practice.
Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE hand over to guest host Kamil Armacki , also known as Nerdabetic, who is joined by Dr. Korey Hood, Clinical Psychologist and Professor at Stanford University, and Jen Boyd, Senior Director of Medical Affairs at Insulet.
Together, they unpack the often overlooked mental and cognitive load of living with diabetes, from constant decision making and planning to sleep disruption and diabetes distress. Dr Hood shares both his clinical expertise and personal perspective as someone living with type 1 (t1d) diabetes, highlighting why these challenges are just as important as glycemic outcomes.
The conversation explores how advancements in automated insulin delivery (AID) and human-centered design are helping reduce that burden. Jen Boyd discusses how simplicity, usability, and patient feedback shape the development of technologies like Omnipod 5, with a focus on removing friction from everyday diabetes management. It is a powerful reminder that diabetes care is not just about time in range, but about creating more time for living.
• 03:03– Mental & cognitive burden of diabetes
• 07:26 – Usability and outcomes are inseparable
• 10:18 – Automated insulin delivery reduces burden and restores freedom
• 18:20 – Shift from numbers to lived experience

How do medical devices like Omnipod 5 improve the lives of people living with diabetes?
How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?
Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who treat patients living with type 1 (t1d) and type 2 diabetes (t2d).
Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.
Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with devices like Omnipod 5. If you’re looking to empower your patients to take back control of their diabetes, then this is the podcast for you.
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.

© 2026 Insulet Corporation. All rights reserved
22 min
April 22 The Benefits of Insulet’s Pod Recycling Program
How do you make diabetes care more sustainable? We’re addressing patient concerns regarding medical waste, enhancing the sustainability profile of the practice's treatment recommendations, and fostering higher patient satisfaction with the Insulet’s Pod Recycling Program.

Hosts Dena Gottesman MS, RD, CDCES and Nancy Hanna RN, BSN, CDE are joined by Lisa Brady, Vice President and Chief Sustainability Officer at Insulet, to explore how the company is tackling one of the biggest challenges in diabetes technology – waste.
Lisa walks through Insulet’s Pod recycling program, which has now expanded across the United States. Omnipod® 5 users can request a simple, accessible return kit, which can hold up to 6 months' worth of Pods. Once returned, Lisa explains the decontamination process and how batteries, plastics and metals are repurposed. This global diabetes tech recycling program is the first of many sustainability initiatives enabling Insulet to take a more active role in reducing environmental impact without increasing the burden of daily diabetes care.

• 01:22 – The core pillars of Insulet’s sustainability strategy
• 03:49 – A step-by-step breakdown of the recycling program
• 05:06 –Why Pod recycling matters to customers and the community
• 09:51 – What’s next: expansion, future access, and sustainability goals
--
How do medical devices like Omnipod 5 improve the lives of people living with diabetes? How can Healthcare Professionals implement Omnipod 5 Automated Insulin Delivery (AID) Systems in practice?
Beyond the Bolus is a US-based diabetes education podcast for healthcare professionals who care for people living with type 1 (t1d) and type 2 diabetes (t2d).
Hosted by Insulet’s Clincial Services Mangers, Nancy Hanna RN, BSN, CDE, and Dena Gottesman MS, RD, CDCES, this dynamic duo care deeply about helping healthcare professionals (HCP)’s and patients simplify life with diabetes. Episodes cover a range of topics such as, how to get started with Omnipod 5 to ongoing care management, helping HCPs make patient conversations more efficient and effective.
Beyond the Bolus also dives into the latest clinical research and data with prominent diabetes experts from across the globe who share real-world experiences and offer insights into what the future of diabetes care could look like with technology like Omnipod 5.

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.

© 2026 Insulet Corporation. All rights reserved.
16 min
February 25 A Clinician Love Letter to Omnipod® 5
Hosted by Nancy Hanna and Dena Gottesman

In this special Valentine’s-month episode of Beyond the Bolus, hosts Nancy Hanna and Dena Gottesman share a clinician “love letter” to the Omnipod 5 Automated Insulin Delivery System — highlighting the real-world moments, patient stories, and everyday features that healthcare providers value most.

Through firsthand perspectives from clinicians who both prescribe and personally use Omnipod 5, this episode explores how automated insulin delivery is changing diabetes care.

Guests share why personalization matters, how tubeless design can improve adoption, and how small features (from Custom Foods to real-time data access) can make a meaningful difference in daily diabetes management.

13 min
January 06 Exercising with AID Systems: Practical Tips for Planned and Unplanned Activity with Dr. Desi Zaharieva
In this special ADA 2025 edition of Beyond the Bolus, host Nancy Hanna sits down with Dr Dessi Zaharieva to talk about the most challenging aspects of diabetes management - Exercise.

In this episode, Dr Zaharieva breaks down key takeaways from her co-authored international consensus statement on using automated insulin delivery (AID) systems during physical activity.

Topics covered included how to manage planned VS unplanned exercise using AID systems, why setting a higher glucose target 1-2 hours before physical activity makes a difference and the importance of a strategic approach to carbs to help prevent hypoglycaemia. Whether you’re supporting patients in the clinic or helping them prepare for spontaneous workouts, this conversation offers evidence-based, real-world strategies to make exercise safer, simpler, and more enjoyable for people living with diabetes.
13 min
December 02, 2025 Expanding Access to AID with Omnipod® 5 (featuring. Dr. Grazia Aleppo)
This episode features Dr. Aleppo, an endocrinologist, who has a commercial relationship with Insulet and was compensated for her participation in the podcast.

Dr. Grazia Aleppo returns to Beyond the Bolus to share her insights from ADA 2025 and beyond. In this engaging conversation, Dr. Aleppo discusses the evolution of automated insulin delivery (AID) systems, the RADIANT and SECURE-T2D clinical trials, and why Omnipod® 5 is changing the game for people with both type 1 and type 2 diabetes. From helping patients to overcome fears of hypoglycemia to simplifying care, Dr. Aleppo emphasizes the importance of challenging outdated assumptions about who benefits from AID and underscores the need for simple, more adaptable solutions for every patient.
32 min
November 19, 2025 Tech, teens, and type 1 diabetes (featuring Dr. Dan DeSalvo)
This episode features Dr. DeSalvo, a pediatric endocrinologist, who has a commercial relationship with Insulet and was compensated for his participation in the podcast.

In this episode of Beyond the Bolus, Dr. Daniel DeSalvo shares his experience caring for teens with type 1 diabetes - and why this population deserves more credit than they often get. From navigating diabetes distress to celebrating wins in the classroom, on the field, and in the orchestra pit, Dr. DeSalvo highlights how Omnipod® 5 can help shift diabetes from the foreground to the background.

With practical tips for system optimization and heartfelt stories of transformation, this episode is a must-listen for anyone caring for teens with type 1 diabetes.
29 min

About Beyond the Bolus - Diabetes Technology Education for Healthcare Providers

From the publisher's feed

Brought to you by the makers of Omnipod, Beyond the Bolus explores topics beyond the basics of diabetes management and takes a closer look at the treatment and care of diabetes through the unique perspectives and great minds of people within the diabetes community.